Pareto Securities AS initiates equity research coverage of ExpreS2ion with a Buy rating and target price of 60 SEK per share
Hørsholm, Denmark, June 24, 2021 – ExpreS2ion Biotech Holding AB (“ExpreS2ion”) hereby announces that Pareto Securities AS has published an equity research initiation report on ExpreS2ion. They initate coverage with a Buy rating and a target price of 60 SEK per share.The major contributors of value in the sum-of-the-parts valuation are ExpreS[2]ion’s 34% stake in its joint venture with NextGen Vaccines, AdaptVac, ExpreS[2]ion’s breast cancer vaccine candidate, ES2B-C001 HER2-cVLP, the company’s Influenza program as part of the INDIGO consortium, and royalties from the PREVENT-nCoV COVID-19